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N- and P/Q-type calcium channels
Voltage-sensitive calcium channels control various biological processes such as
neurotransmitter release and muscle contraction, and are classified on the basis of
electrophysiological properties as L-, N-, P/Q-, R-, or T-type calcium channels. While their
molecular basis has been established in terms of diversity of the α1 subunit, the contribution of
each channel to a total calcium current is often dissected pharmacologically by using specific
blockers. ω-Conotoxins, derived from the venom of marine Conus snails, are one of the most
prominent among various classes of blockers, particularly for blocking of N- and P/Q-type
calcium channels. ω-Conotoxin GVIA and ω-conotoxin MVIIA bind to N-type channels and
ω-conotoxin MVIIC binds to P/Q-type channels with high affinity, and to N-type channels
with low affinity. The N- and P/Q-type calcium channels regulate neurotransmitter release in
presynaptic nerve terminals and play distinct roles in the nervous system, so that discrimination
of these channels by the use of ω-conotoxins is important for understanding their contribution.
In an effort to elucidate structural differences in the pore-forming region between N-type and
P/Q-type channels, a library of MVIIC analogues was synthesised (Combinatorial synthesis of
ω-conotoxin MVIIC analogues and their binding with N- and P/Q-type calcium channels, T.
Sasaki et. al., FEBS Letters, 466, (2000), 125-129). A library of 47 individual compounds was
synthesised on a solid support using a peptide synthesiser followed by chromatographic
purification. A number of analogues were obtained which retained a similar level of affinity to
that of MVIIC for P/Q-type channels, whilst giving improved selectivity over the N-type
channel. Binding activities of MVIIC and these analogues were estimated at 10-8 M for
competition with radiolabelled MVIIC. This work has given new insight into the specific
groups required for selectivity over the N-type channel and may prove useful in the future for
further defining the pharmacophore required for affinity at P/Q-type channels and reducing
affinity for the N-type channel.
--------------------------------------------------------------------------------------------------------------
Delivery agents
Heparin is the anticoagulant of choice for hospitalised patients, but it is dosed only by injection
because it is not absorbed following oral administration. One approach to developing an oral
heparin is to prepare and screen novel, oral, heparin delivery agent candidates. The traditional
approach to elucidation of delivery agents facilitating the oral administration of heparin has
been to screen a combination of one delivery agent and heparin per study group. This
traditional approach requires the preparation, purification and structural identification of each
delivery agent individually. Each in vivo study provides data on only one delivery agent. To
improve the throughput in these studies, a parallel synthesis approach was investigated
(Studies directed at the use of a parallel synthesis matrix to increase throughput in an in vivo
assay, A. Leone-Bay et. al., J. Med. Chem., 43, (2000), 3573-3576). A library of 25
compounds in mixtures of five was prepared in solution by benzoylating a range of amino
acids. Each mixture was tested colonically in rats for its ability to facilitate the gastrointestinal
absorption of heparin. Evidence of heparin delivery was indicated by an increase in blood
clotting time measured by activated partial thromboplastin time (APTT). One of the most
active compounds identified, when active mixtures were resynthesised as single entities, was
(i) which possessed an APTT of over 150 seconds. This work is useful in increasing the
screening throughput significantly in an in vivo assay, allowing the identification of delivery
agents for heparin more rapidly than had been possible previously. In this case testing of 25
compounds was achieved in only 10 experiments. A traditional medicinal chemistry approach
would have required 25 experiments to test 25 compounds.
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